For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of this treatment and Tafamidis meglumine represents a true advancement . These novel therapies protect the transthyretin protein, halting its harmful build-up and reducing the severity